Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated
Read moreNasdaq:SELB
Selecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated
Read moreSelecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated
Read moreSelecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated
Read moreSelecta Biosciences to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated
Read moreSelecta Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
Phase 3 DISSOLVE clinical program with Sobi ongoing to evaluate SEL-212; topline data expected in the second half of 2022
Read moreSelecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter Financial Results and Recent Operational Highlights
WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the
Read moreSelecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios
Read moreSelecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Read moreSelecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
Application of ImmTOR™ plus IGAN’s IgA protease to target immunoglobulin A (IgA) deposition, the critical event leading to IgA Nephropathy (IgAN)
Read more